2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses ixazomib (Ninlaro) in multiple myeloma.
The proteasome inhibitor ixazomib is being evaluated in combination with lenalidomide (Revlimid) and dexamethasone in patients with newly diagnosed multiple myeloma.